Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 44.45%259.14M | ---- | 9.73%221.89M | ---- | 9.57%179.4M | ---- | 87.86%202.22M | ---- | 225.54%163.73M |
| Profit adjustment | ||||||||||
| Interest expense - adjustment | ---- | -19.10%121.74M | ---- | -8.30%306.89M | ---- | -12.29%150.48M | ---- | -18.49%334.66M | ---- | -19.78%171.55M |
| Investment loss (gain) | ---- | -406.13%-67.9M | ---- | -82.41%-106.99M | ---- | 149.48%22.18M | ---- | 42.13%-58.65M | ---- | -88.97%-44.83M |
| Impairment and provisions: | ---- | -92.28%2.02M | ---- | -44.87%37.53M | ---- | 295.00%26.16M | ---- | -53.32%68.08M | ---- | -95.87%6.62M |
| -Other impairments and provisions | ---- | -92.28%2.02M | ---- | ---- | ---- | 295.00%26.16M | ---- | ---- | ---- | -95.87%6.62M |
| Revaluation surplus: | ---- | -126.83%-32.38M | ---- | 105.69%198.81M | ---- | 345.31%120.7M | ---- | -78.09%96.66M | ---- | -110.64%-49.2M |
| Asset sale loss (gain): | ---- | -243.37%-969.55K | ---- | -243.18%-2.31M | ---- | -43.98%676.24K | ---- | 23.95%1.61M | ---- | 139.44%1.21M |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -243.37%-969.55K | ---- | -243.18%-2.31M | ---- | -43.98%676.24K | ---- | 23.95%1.61M | ---- | 139.44%1.21M |
| Depreciation and amortization: | ---- | -7.90%85.84M | ---- | -1.66%183.43M | ---- | 1.52%93.21M | ---- | 9.42%186.53M | ---- | 10.78%91.81M |
| -Amortization of intangible assets | ---- | 5.36%36.71M | ---- | 19.43%71.02M | ---- | 23.94%34.84M | ---- | 23.29%59.47M | ---- | 22.15%28.11M |
| -Other depreciation and amortization | ---- | 5.82%9.74M | ---- | 13.08%19.7M | ---- | 6.82%9.2M | ---- | 13.69%17.42M | ---- | 34.28%8.62M |
| Exchange Loss (gain) | ---- | -1,418.31%-2.21M | ---- | 475.36%1.46M | ---- | 114.25%167.33K | ---- | 77.42%-387.8K | ---- | 60.72%-1.17M |
| Change of operating capital | ||||||||||
| Accounts receivable (increase)decrease | ---- | -38.53%309.55M | ---- | 1,159.08%4.4B | ---- | 235.82%503.58M | ---- | -134.29%-415.29M | ---- | -115.29%-370.78M |
| Accounts payable increase (decrease) | ---- | 59.59%-87.18M | ---- | -23.81%-1.06B | ---- | 58.45%-215.75M | ---- | -187.26%-858.65M | ---- | -15.26%-519.22M |
| Special items of business | ---- | 268.07%40.27M | ---- | 68.03%-7.7M | ---- | -73.24%-23.96M | ---- | 71.22%-24.08M | ---- | 87.69%-13.83M |
| Adjustment items of business operations | 5.32%5.5B | -33.28%587.65M | 50.37%1.13B | 1,042.17%4.18B | 538.06%5.22B | 260.06%880.8M | 139.85%752.02M | -121.25%-443.22M | -48.58%-1.19B | -120.09%-550.29M |
| Net cash from operations | 5.32%5.5B | -26.72%627.91M | 50.37%1.13B | 991.97%4.17B | 538.06%5.22B | 251.89%856.85M | 139.85%752.02M | -123.34%-467.3M | -48.58%-1.19B | -121.48%-564.12M |
| Cash flow from investment activities | ||||||||||
| Dividend received - investment | -89.65%3.54M | -90.14%3.25M | 126.20%1.6M | -57.42%38.74M | -49.79%34.21M | -46.10%33.01M | -96.15%706.14K | 70.80%90.97M | -7.51%68.14M | 124.44%61.24M |
| Sale of fixed assets | -56.86%1.98M | 5.77%1.62M | 275.70%1.45M | 484.72%4.21M | 11,140.03%4.6M | 380.05%1.53M | 68.74%385.13K | 138.01%719.94K | -88.31%40.92K | 41.57%318.1K |
| Purchase of fixed assets | -16.84%-90.01M | -11.39%-57.92M | -75.27%-34.65M | 18.65%-121.53M | 44.34%-77.04M | 50.05%-52M | 24.77%-19.77M | 34.17%-149.39M | 18.67%-138.42M | -11.03%-104.12M |
| Recovery of cash from investments | -31.24%151.66M | 35.78%196.52M | 3,847.68%76.39M | -65.86%665.27M | -85.65%220.55M | -91.09%144.73M | -99.82%1.93M | --1.95B | 194.05%1.54B | 746.77%1.62B |
| Net cash from investment operations | -63.16%67.17M | 12.73%143.47M | 367.39%44.78M | -68.98%586.68M | -87.57%182.32M | -91.95%127.27M | -101.57%-16.75M | 230.25%1.89B | 243.90%1.47B | 1,159.90%1.58B |
| Net cash before financing | 3.00%5.56B | -21.62%771.38M | 59.89%1.18B | 233.95%4.75B | 1,864.82%5.4B | -3.26%984.11M | 189.68%735.27M | 158.58%1.42B | 173.21%274.94M | -63.03%1.02B |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | ---- | ---- | -11.02%7M | -11.02%7M | -11.02%7M | --7M | -91.69%7.87M | -91.79%7.87M | -84.12%7.87M |
| Refund | 25.11%-3.17B | 7.61%-3.15B | -81.48%-3.05B | 38.25%-5.87B | 48.24%-4.24B | 32.25%-3.41B | 11.38%-1.68B | 30.68%-9.5B | 24.42%-8.19B | 38.69%-5.04B |
| Issuance of bonds | -58.94%2.46B | -25.60%2.41B | -87.38%184.34M | -18.89%7.07B | -22.22%6B | -45.10%3.24B | -56.40%1.46B | -28.60%8.72B | -22.98%7.71B | -14.51%5.89B |
| Dividends paid - financing | -4.73%-314.79M | 9.51%-172.01M | 8.69%-129.99M | -11.00%-396.37M | -9.16%-300.56M | 11.04%-190.08M | -6.33%-142.36M | 32.32%-357.08M | 32.34%-275.34M | 19.62%-213.67M |
| Other items of the financing business | 34.08%-43.03M | 15.08%-32.95M | 42.16%-25.24M | 59.91%-80.2M | 61.89%-65.28M | 74.97%-38.8M | 54.67%-43.64M | 1.18%-200.08M | -166.48%-171.31M | -277.23%-154.99M |
| Net cash from financing operations | -176.45%-1.07B | -137.58%-952.61M | -658.45%-3.02B | 155.58%738.15M | 252.59%1.4B | -181.37%-400.96M | -132.52%-398.21M | 37.51%-1.33B | 23.47%-917.09M | 131.10%492.74M |
| Effect of rate | 114.31%157.29K | 1,418.31%2.21M | 50.29%408.46K | -475.36%-1.46M | -253.40%-1.1M | -114.25%-167.33K | -81.47%271.78K | -77.42%387.8K | -76.02%716.41K | -60.72%1.17M |
| Net Cash | -33.92%4.49B | -131.08%-181.23M | -647.27%-1.84B | 5,632.72%5.49B | 1,159.16%6.8B | -61.38%583.16M | -16.74%337.06M | 106.09%95.82M | 59.20%-642.15M | 29.34%1.51B |
| Begining period cash | 41.00%18.89B | 41.00%18.89B | 41.00%18.89B | 0.72%13.39B | 0.72%13.39B | 0.72%13.39B | 0.72%13.39B | -10.58%13.3B | -10.58%13.3B | -10.58%13.3B |
| Cash at the end | 15.78%23.38B | 33.84%18.71B | 24.11%17.04B | 41.00%18.89B | 59.56%20.19B | -5.62%13.98B | 0.20%13.73B | 0.72%13.39B | -4.84%12.66B | -7.68%14.81B |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.